Quick Answer
Apogee Therapeutics, Inc. reported Earnings Per Share Diluted of $4.22 (loss) per share for the year ending 2025.
- Apogee Therapeutics, Inc. showed a decrease of -27.9% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Apogee Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: $1.45 (loss) per share | Q3 2022: $9.46 (loss) per share | Q1 2023: $2.51 (loss) per share | Q2 2023: $3.78 (loss) per share | Q3 2023: $0.51 (loss) per share | Q1 2024: $0.64 (loss) per share | Q2 2024: $0.60 (loss) per share | Q3 2024: $0.86 (loss) per share | Q1 2025: $0.95 (loss) per share | Q2 2025: $1.13 (loss) per share | Q3 2025: $1.11 (loss) per share.
- Over the full 4 years of available data (2022 to 2025), Apogee Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 73.9%.
- Historical annual values: Fiscal year 2025: $4.22 (loss) per share | Fiscal year 2024: $3.30 (loss) per share | Fiscal year 2023: $3.36 (loss) per share | Fiscal year 2022: $16.16 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: